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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S296role of T cells, primarily Th17 cells, are nowwell recognised. On the other
hand data about immunological proﬁle in OA are limited, because OA has
long been regarded in the past as a no inﬂammatory disease. Our study
aim tomeasure thedistribution and the activationdegreeofCD4þ Th17 in
peripheral blood of OA, RA and age-matched healthy controls.
Methods: Patients with established diagnosis of RA according to ACR/
EULAR 2010 criteria, knee or hip OA according to ACR criteria and vol-
unteers healthy blood donors were eligible. Other inclusion criteria were
a DAS28 between 3.2 and 5.1 or a WOMAC Likert score more than 50,
respectively. Exclusion criteria were the presence of other autoimmune
diseases, tumours or secondary osteoarthritis. Finally no changes in
rheumatologic drugs were allowed from 3 months before enrolment.
Multichannel ﬂow cytometry was used for T cells subpopulation dis-
tinguishing and quantiﬁcation using monoclonal antibodies against CD3,
CD4, CD8, CCR6, CD38, CXCR3 and HLA DR. Participants were informed
about the aim of the project and gave their written consent. The project
was accepted by the Local Ethic Committee.
Results: We analysed blood samples of 91 subjects (75 females, 16
males). 15 Patients with well-deﬁned RA, 56 with hip or knee OA and 20
healthy controls. Mean age was 45  2.7 years old (p > 0.05 between
groups). Blood samples from the RA patients had signiﬁcantly higher
count of CD4þCD38þDRþ (activated CD4 T cells) and Th17
(CCR6þCXCR3-) cells as compared to OA patients and control group
(Figure) (P < 0.01). Furthermore the samples from the OA patients had
an higher percentage of activated CD4 T cells and Th17 cells as com-
pared to control group (P < 0.05)
Conclusion: According to the latest view of OA disease pathogenesis,
our preliminary results give support to the hypothesis that OA may also
(like RA) be a disease with an immunological/inﬂammatory involve-
ment. In fact it seems that there is a quantitative but non qualitative
difference in Th17 cells proﬁle, including the expression of activation
markers, between RA and OA.
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PERIODONTITIS DISEASE AS A MODEL OF INFLAMMATION AND
BONE REMODELLING TO STUDY OSTEOARTHRITIS DRUG EFFECTS.
RESULTS FROM A PILOT STUDY IN OA PATIENTS TREATED WITH
CHONDROITIN SULFATE
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Purpose: Periodontitis is an inﬂammatory disease that affects 70% of the
adult population. Its most important consequence is the loss of bone
supporting the teeth. Its medical treatment so far has not shown to be
effective so only different surgical techniques are useful in advanced
stages. Osteoarthritis (OA) and periodontitis share physiopathological
characteristics. OA patients also suffer from an important inﬂammatory
component in the soft tissue and bone structural modiﬁcations. Because
of the evolution of the disease, development of new treatments is dif-
ﬁcult. Periodontitis could be a model for the study of OA, where thechanges of tissues could be observed in amore directlyway. Chondroitin
sulfate (CS) has shownapositive effect in different chronic inﬂammatory
diseases such as psoriasis, inﬂammatory bowel disease and OA. Perio-
dontitis is the most prevalent inﬂammatory disease, but currently
without speciﬁc treatment. New approaches for a safety and effective
pharmacological treatments are required. The purpose of this study was
to demonstrate that an effective drug inOApathologymay improve both
the inﬂammatory symptoms and the bone resorption occurred in
periodontal disease. This improvement would be reﬂected in changes in
biochemical markers of inﬂammation and bone metabolism.
Methods: Observational, prospective, pilot study in 26 patients diag-
nosed with knee OA and periodontitis. Patients were treated with CS
800 mg/day(Condrosan, Bioiberica SA) for 12 months. The L€oe and
Silness gingival index (used to assess soft tissue damage) and CPITN
(Community Periodontal Index of Treatment Needs) index were eval-
uated at 0, 3, 6, 9 and 12 months with saliva collection. Orthopanto-
mographys were performed at 0, 6 and 12 months to evaluate bone
damage. Vertical lesions were measured using a periodontal probe at 0,
6 and 12 months. Different concentration of inﬂammatory markers
(TNF -a, IL -1b, IL-18 and PGE2) and bonemetabolism (OPG, OPN, RANKL
and MMP-8) were quantiﬁed in the saliva by ELISA or protein array.
During the study, patients were asked to continue their usual oral
hygiene without additional treatments. Statistical analysis was per-
formed using Wilcoxon test for paired samples.
Results: L€oe and Silness index decreased signiﬁcantly after 6, 9 and 12
monthsof treatment (p¼0.004,0.007and0.002 respectively). In contrast,
no signiﬁcant changeswere observed in CPTIN values, probably due to the
fact that only the most affected tooth is studied and it can differ between
visits. Both orthopantomography as well as the vertical lesions evolution,
showed signiﬁcant improvement at 12 months (p ¼ 0.009) and 6 and 12
months respectively (p ¼ 0.002 and p ¼ 0.016). For biochemical analysis
results, patients with no gingival improvement were used as control
group.The results showabetterperformance in thegroupof responders to
treatment for inﬂammatory markers PGE-2, TNF-a and IL-1b , as well as
bone metabolismmarkers, OPN, MMP -8, and the ratio OPG/RANKL. Res-
ponders groups PGE2 levels showed a signiﬁcant decreased after 12
months of treatment (p¼ 0.033), whereas IL-1b levels in non responding
patients suffered a signiﬁcant increased after 3 and 6months of treatment
(p¼ 0.017)
Conclusions: CS improves soft tissue inﬂammation after 6 months of
treatment and bone support at 12 months in periodontal disease,
similar to the already known effect of the drug in OA disease. This
improvement is reﬂected in markers of inﬂammation and bone
metabolism in saliva. Due to its efﬁcacy and safety proﬁle, CS is
postulated as a good candidate for the treatment of this disease.Intervertebral disc
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ADIPOKINES AND THE INTERVERTEBRAL DISC: DOES A
BIOCHEMICAL LINK EXIST BETWEEN OBESITY AND BACK PAIN?
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Purpose: Obesity is a signiﬁcant risk factor for development of low back
pain and intervertebral disc (IVD) degeneration. The mechanism
underlying this link is unclear but is commonly thought to arise from
altered loading. However, adipokines such as leptin and adiponectin,
produced by adipose tissue, are now known to be involved in degra-
dative processes particularly in articular joints. We propose a similar
link exists between these adipokines and intervertebral disc degener-
ation. Obese individuals are known to have higher concentrations of
serum adipokines, there is increased local fat in chronic spinal con-
ditions potentiating an increase in local adipokine levels and disc cells
are reported to have leptin receptors and can synthesise leptin.
The aim of the study was to identify responses of nucleus pulposus (NP)
and outer annulus ﬁbrosus (OA) cells to leptin and adiponectin. Once
identiﬁed, we proceeded to determine if synergistic effects exist in the
presence of other pro-inﬂammatory cytokines.
Methods: Bovine intervertebral discs were used as a model system.
Freshly isolated NP and OA cells embedded in 3D alginate beads, were
